Login
$MRKR
$0.82 -$0.01 (1.04%) After hours

$MRKR SEC Filings

Filed On Filing
16 Nov 2026 10-Q
19 Oct 2026 8-K: Other Events

Competitive selection reinforces independent recognition of the scientific rationale and development potential of Marker’s multi-antigen recognizing T cell platform

14 Aug 2026 10-Q
15 May 2026 10-Q
04 May 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF MARKER THERAPEUTICS, INC.

20 Mar 2026 DEFA14A
20 Mar 2026 ARS
20 Mar 2026 Proxy statement: annual meeting on May 1, 2026

say-on-pay vote

19 Mar 2026 8-K: Results of Operations and Financial Condition

Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses

18 Mar 2026 10-K
10 Mar 2026 FORM PRE 14A
09 Feb 2026 8-K: Shareholder Director Nominations

On February 9, 2026, the Board of Directors of Marker Therapeutics, Inc. (the “Company”) determined it is in the best interest of the Company to schedule Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) for May 1...

19 Nov 2025 Form 4: Knobil Katharine, Director

Granted 221,741 Stock Option (Right to Buy)

19 Nov 2025 Form 4: Eansor Norman David, Director

Granted 221,741 Stock Option (Right to Buy)

19 Nov 2025 Form 4: Elms Steve, Director

Granted 221,741 Stock Option (right to buy)

17 Nov 2025 SCHEDULE 13D/A
14 Nov 2025 SCHEDULE 13G/A
14 Nov 2025 8-K: Results of Operations and Financial Condition

APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma

13 Nov 2025 10-Q
05 Nov 2025 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

Houston, TX — November 5, 2025 – Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and s...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support